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Therapeutic effects of HL for a collagen-induced arthritis (CIA) mouse models of HL-23 composed of
95 mol % L-a-dimyristoylphosphatidylcholine (DMPC) and 5 mol % polyoxyethylenedodecylether
(C12(EO)23) in vivo were examined. Remarkably high therapeutic effects of HL-23 for CIA mouse models
were obtained on the basis of clinical assessment of arthritis. The reduction of hyperplastic synovial
membrane (pannus tissue) and destruction of the cartilage and bone by HL-23 was revealed on the basis
of hematoxylin and eosin (HE) and safranin O staining. Furthermore, the downregulation of inﬂammatory
cytokines such as interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and IL-6 for CIA mouse models trea-
ted with HL-23 were investigated. Remarkably high therapeutic effects without joint swelling were
obtained in CIA mouse models treated with HL-23.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Rheumatoid arthritis (RA) is an autoimmune disease character-
ized by chronic inﬂammation of synovial joints, affecting up to 1%
of the population worldwide. It is characterized by an inﬂamma-
tion of joints, hyperplastic synovium with pannus formation, lead-
ing to bone and cartilage destruction in the joints. The affected
synovial tissues contain activated macrophages, ﬁbroblasts, T lym-
phocytes, and B lymphocytes, which release proinﬂammatory
cytokines such as interleukin (IL)-1b, tumor necrosis factor
(TNF)-a, and IL-6.1,2
Current clinical chemotherapy of RA using disease-modifying
antirheumatic drugs (DMARDs) and anti-TNF-a antibody reduce
inﬂammation by inhibiting or halting the immune process.1–5
However, potentially negative side effects of anti-RA drug such
as digestive organs dysfunction, liver dysfunction, kidney dysfunc-
tion, stomatitis, depilation, respiratory related symptoms including
pneumonitis, and myelosuppression have been reported.1,2,5–7
Furthermore, tolerance to anti-RA drug in patients have been
observed.1,2,8,9 Therefore, anti-RA drug that would be effective for
suppressing the inﬂammation of joints in RA without side effects
is highly desirable to improve the quality of life for RA patients.
We have produced hybrid liposomes (HL) which can be pre-
pared by just the sonication of vesicular and micellar molecules
in a buffer solution.10,11 HL contain no organic solvent unlikeconventional liposomes and remain stable for longer periods. The
physical properties of these liposomes such as size, membrane ﬂu-
idity, phase transition temperature, and hydrophobicity can be
controlled by changing the constituents and compositional ratios
of the HL. The therapeutic effects of HL composed of L-a-dimyris-
toylphosphatidylcholine (DMPC) and polyoxyethylene(20) sorbi-
tan monolaurate (Tween 20) including antitumor drugs such as
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) have been observed
on the growth of glioma cells in vivo.12 On the other hand, high
inhibitory effects of HL composed of DMPC and polyoxyethylene(n)
dodecyl ethers (C12(EO)n) without any drugs on the growth of
tumor cells in vitro13,14 and in vivo15,16 along with the induction
of apoptosis have been obtained. After receiving the approval of
the Bioethics Committee, successful clinical chemotherapy with
drug-free HL to patients with lymphoma has been reported.17
More recently, we have reported that HL inhibits the growth of
human RA ﬁbroblast-like synoviocytes (HFLS-RA) cells along with
apoptosis in vitro.18 However, the research for the effects of HL
using SKG mice as models of RA and regulation of inﬂammatory
cytokines is very limited, because it takes more than three months
until symptoms are observed. To overcome this disadvantage, in
this study, we examined the therapeutic effects of HL-23 composed
of 95 mol % L-a-dimyristoylphosphatidylcholin (DMPC) and
5 mol % polyoxyethylenedodecylether (C12(EO)23) for a collagen-
induced arthritis (CIA) mouse models19 of RA in vivo.
HL-23 were prepared by using sonication (VELVO VS-N300,
300W, Velvo-clear, Tokyo, Japan) of a mixture containing
Figure 1. Therapeutic effects of HL-23 for CIA mouse models with rheumatoid
arthritis using clinical score method. (A) Rheumatic clinical score changes for 7
weeks after the booster injection. Data presented are mean ± S.D. Dose for DMPC;
136 mg/kg. (B) Photographs of ﬁnger at 7 weeks after booster injection.
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Tokyo, Japan, purity>99%) and 10 mol % polyoxyethylenedodecyl
ether (C12(EO)23, Sigma–Aldrich Japan, Tokyo, Japan) in 5% glucose
solution at 45 C with 300 W, followed by ﬁltration with a 0.20 lm
ﬁlter.
Physical properties of HL-23 composed of 95 mol % DMPC,
5 mol % C12(EO)23 were examined. Apparent mean hydrodynamic
diameters (dhy) of HL were measured using light scattering
spectrometer (ELS-8000, Otsuka Electronics Co. Ltd, Japan) with
He-Ne laser light source (633 nm). The diameter was calculated
by Stokes–Einstein equation (dhy = (jT)/(3pgD)), where j isFigure 2. Therapeutic effects of HL-23 for CIA mouse models with rheumatoid arthr
Histochemical stain using the HE protocol. (B) Histochemical stain using the safranin OBoltzmann constant, T is absolute temperature, g is viscosity and
D is diffusion coefﬁcient. Hydrodynamic diameter (dhy) of HL-23
was under 100 nm, which were preserved for a period remaining
stable for more than one month. On the other hand, DMPC lipo-
somes were unstable and precipitated after 14 days.
We examined the therapeutic effects of HL-23 using CIA (colla-
gen-induced arthritis) mouse models of RA, which are the most
commonly studied autoimmune models of rheumatoid arthritis.19
The mice were handled in accordance with the guidelines for ani-
mal experimentation set out in Japanese law. The animal studies
were approved by the Committee on Animal Research of Sojo
University.
Joint swelling was monitored by inspection and scored.20 The
results are shown in Figure 1. No detection of rheumatic clinical
score indicating joint swelling and deformity of ﬁngers was
obtained in the CIA mouse models treated with HL-23, although
increased rheumatic score were observed in the control group from
4 weeks after booster injection (Fig. 1A). No joint swelling was
obtained in the mice treated with HL-23 on the basis of macro-
scopic inspection, although joint swelling and deformity of ﬁngers
in all feet were observed in the control group (Fig. 1B). It is note-
worthy that remarkable therapeutic effects were obtained in the
CIA mouse models of RA intraperitoneally treated with HL-23
without drugs.
Then, we histologically evaluated the therapeutic effects of HL-
23 using the ﬁnger tissues for the CIA mouse models in vivo. The
ﬁnger sections were stained with hematoxylin-eosin (HE) or safra-
nin O protocol, and observed by optical microscope (Nikon TS-100,
Tokyo, Japan).21 The results are shown in Figure 2. Pannus as thick-
ening synovial tissue that covers articular cartilage were observed
in the ﬁnger tissues of the untreated control group using HE stain-
ing (Fig. 2A). In contrast, no abnormal ﬁndings were observed in
the ﬁnger tissues of the group treated with HL-23 as the same as
the normal group (Fig. 2A). Cartilage proteoglycan positive cells
(red color) of the ﬁngers tissue in the group treated with HL-23
(Fig. 2B) increased compared with that of the control group
(Fig. 2B), although severe cartilage loss characterized by cartilage
degradation were observed in the ﬁnger tissues in the untreated
control group (Fig. 2B). These results indicate that HL-23 are
remarkably effective for inhibiting the pannus formation and
destruction of cartilage and bone in CIA mouse models of RA.
Furthermore, we carried out immunostaining using inﬂamma-
tory cytokines such as interleukin (IL)-1b, tumor necrosis factoritis on the basis of HE and safranin O staining of tissue sections in ﬁnger. (A)
protocol. Dose for DMPC; 136 mg/kg. Scale bar: 50 lm.
Figure 3. Therapeutic effects of HL for CIA mouse models with rheumatoid arthritis in tissue sections in ﬁnger using immunostaining of IL-1b. Dose for DMPC; 136 mg/kg.
Arrows indicate IL-1b positive cells. Scale bar: 50 lm.
Figure 4. Therapeutic effects of HL for CIA mouse models with rheumatoid arthritis in tissue sections in ﬁnger using immunostaining of TNF-a. Dose for DMPC; 136 mg/kg.
Arrows indicate TNF-a positive cells. Scale bar: 50 lm.
Figure 5. Therapeutic effects of HL for CIA mouse models with rheumatoid arthritis in tissue sections in ﬁnger using immunostaining of IL-6. Dose for DMPC; 136 mg/kg.
Arrows indicate IL-6 positive cells. Scale bar: 50 lm.
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The immunostained sections were counterstained with hema-
toxylin, rinsed in distilled water and mounted. The stained ﬁnger
sections were observed by optical microscope.
As shown in Figure 3, many IL-1b positive cells (brown color)
were observed in the ﬁnger tissues near the cartilage and bone of
the nontreated control group. On the other hand, few IL-1b positive
cells were observed in the normal and the group treated with HL-
23.
Numerous TNF-a positive cells (brown color) were observed in
the ﬁnger tissues near the cartilage and bone in the control group
as shown in Figure 4, although TNF-a negative cells of the ﬁnger
tissue in the group treated with HL-23 were almost the same as
that of the normal group.
In addition, many IL-6 positive cells were observed in the
inﬂammation subcutaneous tissue of ﬁngers of the control group.
On the other hand, no IL-6 positive cells were observed in the nor-
mal and the group treated with HL-23 as shown in Figure 5. These
results indicate that HL have remarkable downregulation effects
for inﬂammatory cytokines such as interleukin (IL)-1b, tumor
necrosis factor (TNF)-a, and IL-6 for CIA mouse models.
In conclusion, we clearly demonstrated that HL-23 showed
therapeutic effects for the CIA mouse models of RA in vivo along
with downregulation of inﬂammatory cytokines. The noteworthy
aspects are as follows. (a) Remarkably high therapeutic effects of
HL-23 for CIA mouse models were obtained on the basis of clinicalassessment of arthritis. (b) The reduction of hyperplastic synovial
membrane (pannus tissue) and destruction of the cartilage and
bone by HL-23 was revealed on the basis of hematoxylin and eosin
(HE) and safranin O staining. (c) The downregulation of inﬂamma-
tory cytokines such as interleukin (IL)-1b, tumor necrosis factor
(TNF)-a, and IL-6 for CIA mouse models treated with HL-23 were
obtained. It is noteworthy that remarkable high inhibitory effects
of HL-23 without drug along with downregulation of inﬂammatory
cytokines for the CIA mouse models of RA were obtained for the
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